philipn / List of COVID-19 ARB trials 2d3f2fe82d1fe7c92c6280ecf723a4584a76e8ee

Create Draft
Adding C21 animal lung paper picture

Photo CC-BY Rathinasabapathy et al.

Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this
While not a trial of ARBs as therapy, BRACE CORONA was a randomized controlled trial exploring stopping-versus-continuing ACE inhibitors/ARBs in patients with hypertension. It showed no harm in continuation of ACE inhibitors and ARBs with COVID-19. There was a non-statistically significant hint of a benefit in the ACEi/ARB group but the trial was not powered to detect this.
The first randomized controlled trial of an ARB for treatment of COVID-19 returned preliminary results showing possible improvements in time to discharge, need for supplementary oxygen and CRP. See "Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report." See independent critical appraisal of trial.

List of Angiotensin-receptor blocker (ARB) trials for COVID-19:

ACE inhibitor trials:

Other trials of renin-angiotensin modulation for COVID-19:

See also
While not a trial of ARBs as therapy, BRACE CORONA was a randomized controlled trial exploring stopping-versus-continuing ACE inhibitors/ARBs in patients with hypertension. It showed no harm in continuation of ACE inhibitors and ARBs with COVID-19. There was a non-statistically significant hint of a benefit in the ACEi/ARB group but the trial was not powered to detect this.
The first randomized controlled trial of an ARB for treatment of COVID-19 returned preliminary results showing possible improvements in time to discharge, need for supplementary oxygen and CRP. See "Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report." See independent critical appraisal of trial.

List of Angiotensin-receptor blocker (ARB) trials for COVID-19:

ACE inhibitor trials:

Other trials of renin-angiotensin modulation for COVID-19:

C21, an AT2R agonist, has shown benefit in animal lung injury models, similar to ARBs. In a recent randomized, placebo-controlled clinical trial, C21 showed promise as COVID-19 treatment. Photo CC-BY Rathinasabapathy, et al.

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.